Summit Trail Advisors LLC Sells 64 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Trail Advisors LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,038 shares of the biopharmaceutical company’s stock after selling 64 shares during the quarter. Summit Trail Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $912,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fortitude Family Office LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares during the last quarter. Criterion Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $37,000. Finally, Sutton Wealth Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on REGN. Bank of America increased their target price on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $981.71.

Regeneron Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ REGN traded up $1.64 during mid-day trading on Monday, hitting $958.64. The stock had a trading volume of 351,998 shares, compared to its average volume of 498,218. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The business has a 50 day moving average price of $943.75 and a two-hundred day moving average price of $897.24. The firm has a market cap of $105.22 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the firm earned $10.96 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 854 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $979.25, for a total transaction of $836,279.50. Following the sale, the director now owns 1,382 shares in the company, valued at approximately $1,353,323.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total transaction of $836,279.50. Following the sale, the director now directly owns 1,382 shares in the company, valued at $1,353,323.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 9,095 shares of company stock valued at $8,729,766. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.